Investigational TMS Treatment for Depression

Dorsolateral Versus Medial Prefrontal TMS for Depression

This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.

While transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex (DLPFC) is an FDA approved treatment for depression, a growing and converging database suggests the medial prefrontal cortex (MPFC) may be even more critical to the neurobiology of depression and antidepressant treatment response. This study will compare the efficacy of high frequency transcranial madntic stimulation on these two sections of the brain.

Inclusion Criteria:

• 21-70 years old
• inadequate response to one current antidepressant medication
• currently depressed

Exclusion Criteria:

• psychiatric comorbidities